[go: up one dir, main page]

Hruby et al., 2002 - Google Patents

Topographical considerations in de novo design of peptides

Hruby et al., 2002

View PDF
Document ID
9054419333816076971
Author
Hruby V
Liao S
Shenderovich M
Qian X
Bonner G
Han G
Bilsky E
Porreca F
Publication year
Publication venue
Peptides Biology and Chemistry: Proceedings of the 1996 Chinese Peptide Symposium July 21–25, 1996, Chengdu, China

External Links

Snippet

For de novo design of peptide and protein agonists, most investigators have concentrated their efforts on designing or mimicing the peptide backbone secondary structures (space) such as a-helix,-turn and-sheet structures [l-5]. Using this approach, considerable success …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Similar Documents

Publication Publication Date Title
US5364851A (en) Conformationally restricted biologically active peptides, methods for their production and uses thereof
O'Leary et al. Design of potent peptide mimetics of brain-derived neurotrophic factor
Benedetti X‐ray crystallography of peptides: The contributions of the Italian laboratories
Hruby et al. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads
Nakagawa et al. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions
Salvadori et al. δ Opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides
US6320024B1 (en) Method for design of substances that enhance memory and improve the quality of life
Kinney et al. Structure–function analysis of urotensin II and its use in the construction of a ligand–receptor working model
Cai et al. Biological and conformational study of β‐substituted prolines in MT‐II template: steric effects leading to human MC5 receptor selectivity
Vagner et al. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of α-MSH
Qian et al. Probing the stereochemical requirements for receptor recognition of δ opioid agonists through topographic modifications in position 1
Arttamangkul et al. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the “address” sequence
Schiller et al. Novel ligands lacking a positive charge for the δ-and μ-opioid receptors
Janecka et al. Conformationally restricted peptides as tools in opioid receptor studies
US20210179666A1 (en) Cyclic peptides and methods of use thereof
Cai et al. Design of cyclized selective melanotropins
Bélec et al. A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys6-Pro7 amide cis-isomer population
Deschamps The role of crystallography in drug design
Singh et al. Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: Modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R)
Erchegyi et al. Novel sst4-selective somatostatin (SRIF) agonists. 2. Analogues with β-methyl-3-(2-naphthyl) alanine substitutions at position 8
Ueda et al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach
Kapurniotu et al. Rational design, conformational studies and bioactivity of highly potent conformationally constrained calcitonin analogues
Bisello et al. Mono-and bicyclic analogs of parathyroid hormone-related protein. 1. Synthesis and biological studies
Zhang et al. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications
Hruby et al. Topographical considerations in de novo design of peptides